Revisiting GDF9 variants in primary ovarian insufficiency: A shift from dominant to recessive pathogenicity?

GDF9 Penetrance Premature ovarian insufficiency

Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
26 Jun 2024
Historique:
received: 02 05 2024
revised: 27 05 2024
accepted: 25 06 2024
medline: 29 6 2024
pubmed: 29 6 2024
entrez: 28 6 2024
Statut: aheadofprint

Résumé

Primary ovarian insufficiency (POI) affects around 2-4% of women before the age of 40. Genetic factors play an important role in POI. The GDF9 gene has been identified as a significant genetic contributor of POI. However, the pathogenicity and penetrance of GDF9 variants remain uncertain. A next-generation sequencing approach was employed to investigate the entire coding region of the GDF9 gene in a cohort of 1281 patients with POI or diminished ovarian reserve (DOR). The frequency of each identified GDF9 variant was then compared with that of the general population, taking into account the ethnicity of each individual. By screening the entire coding region of the GDF9 gene, we identified 19 different variants, including 1 pathogenic frameshift variant. In total, 36 patients with POI/DOR (2.8%) carried at least one GDF9 variant. With regard to missense variants, no significant overrepresentation of the most common variants was observed in our POI/DOR cohort in comparison to the general or specific ethnic subgroups. Only one homozygous subject had a frameshift loss of function variant. This epidemiological study suggests that the vast majority of heterozygous missense variants could be considered as variants of uncertain significance and the homozygous loss-of-function variant could be considered as a pathogenic variant. The identification of a novel case of a homozygous POI patient with a heterozygous mother carrying the same variant with normal ovarian function strongly suggests that GDF9 syndrome is an autosomal recessive disorder.

Sections du résumé

BACKGROUND BACKGROUND
Primary ovarian insufficiency (POI) affects around 2-4% of women before the age of 40. Genetic factors play an important role in POI. The GDF9 gene has been identified as a significant genetic contributor of POI. However, the pathogenicity and penetrance of GDF9 variants remain uncertain.
METHODS METHODS
A next-generation sequencing approach was employed to investigate the entire coding region of the GDF9 gene in a cohort of 1281 patients with POI or diminished ovarian reserve (DOR). The frequency of each identified GDF9 variant was then compared with that of the general population, taking into account the ethnicity of each individual.
RESULTS RESULTS
By screening the entire coding region of the GDF9 gene, we identified 19 different variants, including 1 pathogenic frameshift variant. In total, 36 patients with POI/DOR (2.8%) carried at least one GDF9 variant. With regard to missense variants, no significant overrepresentation of the most common variants was observed in our POI/DOR cohort in comparison to the general or specific ethnic subgroups. Only one homozygous subject had a frameshift loss of function variant.
CONCLUSION CONCLUSIONS
This epidemiological study suggests that the vast majority of heterozygous missense variants could be considered as variants of uncertain significance and the homozygous loss-of-function variant could be considered as a pathogenic variant. The identification of a novel case of a homozygous POI patient with a heterozygous mother carrying the same variant with normal ovarian function strongly suggests that GDF9 syndrome is an autosomal recessive disorder.

Identifiants

pubmed: 38942181
pii: S0378-1119(24)00615-2
doi: 10.1016/j.gene.2024.148734
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

148734

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Bienvenu reports was provided by Public Assistance Hospitals Paris. Bienvenu reports a relationship with Public Assistance Hospitals Paris that includes: employment and non-financial support. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Pénélope Jordan (P)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France.

Camille Verebi (C)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France.

Bérénice Hervé (B)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France.

Sandrine Perol (S)

Unité de gynécologie médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014 Paris, France.

Valérie Bernard (V)

Service de Chirurgie gynécologique et Médecine de la reproduction · Gynécologie médicale, CHU Bordeaux, Bordeaux, France.

Daphné Karila (D)

Service d'endocrinologie, diabétologie et médecine de la reproduction, APHP. Sorbonne Université, Hôpital Saint-Antoine, 75012 Paris, France.

Eva Jali (E)

Service d'Endocrinologie, Hôpital de la Cavale Blanc, 29200 Brest, France.

Aude Brac de la Perrière (A)

Service d'Endocrinologie, de diabétologie et des maladies métaboliques A, Hospices Civiles de Lyon, 69000 Lyon, France.

Virginie Grouthier (V)

Service d'Endocrinologie, Diabétologie et Nutrition, Hôpital Haut-Lévêque, CHU de Bordeaux, 33000 Bordeaux, France.

Sophie Jonard-Catteau (S)

Département d'assistance médicale à la procréation, Hôpital Jeanne de Flandre, 59000 Lille, France.

Philippe Touraine (P)

Département d'Endocrinologie et médecine de la reproduction, APHP. Sorbonne Université, Pitié-Salpêtrière Hospital, Center for Rare Endocrine and Gynecological Disorders, ERN-HCP, Paris, France.

Corinne Fouveaut (C)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France.

Geneviève Plu-Bureau (G)

Unité de gynécologie médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014 Paris, France.

Jean Michel Dupont (J)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France.

Anne Bachelot (A)

Département d'Endocrinologie et médecine de la reproduction, APHP. Sorbonne Université, Pitié-Salpêtrière Hospital, Center for Rare Endocrine and Gynecological Disorders, ERN-HCP, Paris, France.

Sophie Christin-Maitre (S)

Service d'endocrinologie, diabétologie et médecine de la reproduction, APHP. Sorbonne Université, Hôpital Saint-Antoine, 75012 Paris, France.

Thierry Bienvenu (T)

Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 75014 Paris, France. Electronic address: thierry.bienvenu@inserm.fr.

Classifications MeSH